Nelson M R, McNeil J J, Peeters A, Reid C M, Krum H
Department of Epidemiology and Preventive Medicine, Monash Medical School, Alfred Hospital, Melbourne, VIC.
Med J Aust. 2001 Jun 4;174(11):565-8. doi: 10.5694/j.1326-5377.2001.tb143436.x.
To determine the extent to which "current guidelines" for the management of hypertension are reflected in the prescribing of antihypertensive drugs in Australia over the period 1994-1998, and to examine the cost implications of actual and recommended prescribing patterns.
Federal Government and consumer cost estimates modelled on prescribing patterns and guideline recommendations over the period 1994-1998.
Prescribing on Federal Government pharmaceutical schemes over the 1994-1998 period.
Estimates of Pharmaceutical Benefits Scheme/Repatriation Pharmaceutical Benefits Scheme cost changes in Australian dollar values.
The implementation of current guidelines for patients with uncomplicated hypertension taking monotherapy alone could have reduced drug costs by $45-$108 million in 1998.
Current prescribing patterns indicate that clinical practice has pre-empted the results from clinical trials of newer, more expensive agents and that clinicians' prescribing patterns do not closely reflect current recommendations.
确定1994 - 1998年期间澳大利亚抗高血压药物处方中体现“现行指南”管理高血压程度的情况，并研究实际处方模式和推荐处方模式的成本影响。
基于1994 - 1998年期间的处方模式和指南建议对联邦政府及消费者成本进行估算。
1994 - 1998年期间联邦政府药物计划中的处方情况。
以澳元价值估算的药品福利计划/遣返药品福利计划成本变化。
对于单纯接受单一疗法的无并发症高血压患者，实施现行指南本可在1998年使药品成本降低4500万至1.08亿澳元。
当前的处方模式表明临床实践先于更新、更昂贵药物的临床试验结果，且临床医生的处方模式未紧密反映当前建议。
